Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06312137
Title A Study to Assess Efficacy and Safety of Pembrolizumab With or Without MK- 2870 in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Merck Sharp & Dohme LLC
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST